Press Statement | 30 September 2010 | PDF
The monitoring of medicines safety in the Europe Union (EU) took a step forward following last week’s approval by Parliament of the amendments to EU legislation on Pharmacovigilance. One notable and positive outcome is the legal provision that will enable patients and consumers to directly report their adverse reactions to medicines.